Juju Shang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juju Shang has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Hongxu Liu
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
7 shared publications Hongxu Liu
Department of Cardiovascular Medicine, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
5 shared publicationsSinai Li
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
4 shared publicationsWenlong Xing
Department of Cardiovascular, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, People’s Republic of China
4 shared publicationsXiaolei Lai
Department of Cardiovascular Medicine, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
4 shared publicationsHaoyue Shi
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
3 shared publications
Latest Publications
- Open Access
Are study design characteristics in single-arm trials comparable with those of their objective performance criteria or performance goals? A scoping review
Objectives: Single-arm trials (SATs) with objective performance criteria (OPCs) or performance goals (PGs) are increasingly used for regulatory approval of medical devices and other interventions. However, the comparability of study design characteristics between SAT and their external comparator sources remains unclear. This scoping review aimed to evaluate the comparability of study design characteristics between SATs and their matched OPC/PG sources. Design: Scoping review. Data sources: PubMed, Embase, the Cochrane Library and four Chinese databases—China National Knowledge Infrastructure, Wanfang Data, CQVIP and SinoMed—were searched from inception to 30 April 2026. Eligibility criteria: We included SATs that used one or more OPCs or PGs as external comparators to evaluate safety and/or effectiveness endpoints and reported specific numerical values of OPCs or PGs. Data extraction and synthesis: Two reviewers independently screened the retrieved records and extracted data using a standardised form. For each included SAT, we retrieved the cited OPC/PG sources and extracted study design characteristics data (age, sex, health conditions, outcome definitions and measurement time points) for comparison. Age and sex were compared using summary t-tests and χ² tests; health conditions were assessed by two clinicians based on eligibility criteria and baseline characteristics. Results were stratified by OPC versus PG. Results: A total of 1243 records were identified, and 133 SATs were included. Most studies used PGs (84, 63.2%); 34 (25.6%) claimed to use OPCs, and 15 (11.3%) could not be classified. Of the 60 age comparisons available from 41 studies, 30 showed statistically significant differences; of the 82 sex comparisons available from 59 studies, 60 showed significant differences. Health conditions, outcome definitions and time points were assessed descriptively in a subset of studies, and discrepancies were also observed. Conclusion: Suboptimal comparability of study design characteristics was observed between SATs and their OPC/PG sources, which might influence the treatment effect estimates. Greater attention to the comparability of study design characteristics in SATs with OPC/PGs may improve the validity of evidence.
Open AccessAre study design characteristics in single-arm trials comparable with those of their objective performance criteria or performance goals? A scoping review
Objectives: Single-arm trials (SATs) with objective performance criteria (OPCs) or performance goals (PGs) are increasingly used for regulatory approval of medical devices and other interventions. However, the comparability of study design characteristics between SAT and their external comparator sources remains unclear. This scoping review aimed to evaluate the comparability of study design characteristics between SATs and their matched OPC/PG sources. Design: Scoping review. Data sources: PubMed, Embase, the Cochrane Library and four Chinese databases—China National Knowledge Infrastructure, Wanfang Data, CQVIP and SinoMed—were searched from inception to 30 April 2026. Eligibility criteria: We included SATs that used one or more OPCs or PGs as external comparators to evaluate safety and/or effectiveness endpoints and reported specific numerical values of OPCs or PGs. Data extraction and synthesis: Two reviewers independently screened the retrieved records and extracted data using a standardised form. For each included SAT, we retrieved the cited OPC/PG sources and extracted study design characteristics data (age, sex, health conditions, outcome definitions and measurement time points) for comparison. Age and sex were compared using summary t-tests and χ² tests; health conditions were assessed by two clinicians based on eligibility criteria and baseline characteristics. Results were stratified by OPC versus PG. Results: A total of 1243 records were identified, and 133 SATs were included. Most studies used PGs (84, 63.2%); 34 (25.6%) claimed to use OPCs, and 15 (11.3%) could not be classified. Of the 60 age comparisons available from 41 studies, 30 showed statistically significant differences; of the 82 sex comparisons available from 59 studies, 60 showed significant differences. Health conditions, outcome definitions and time points were assessed descriptively in a subset of studies, and discrepancies were also observed. Conclusion: Suboptimal comparability of study design characteristics was observed between SATs and their OPC/PG sources, which might influence the treatment effect estimates. Greater attention to the comparability of study design characteristics in SATs with OPC/PGs may improve the validity of evidence.
- Open Access
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1793094
Effect and safety of Yiqi-Shengjin granules in hypertension management among patients with abnormal glucose metabolism: a study protocol for a randomized, double-blind, placebo-controlled clinical trial
Background: The co-occurrence of hypertension and abnormal glucose metabolism—a spectrum encompassing prediabetes and diabetes—substantially elevates the risk of cardiovascular disease (CVD). Effective management of this high-risk clinical overlap remains a therapeutic challenge. Yiqi-Shengjin granules (YQSJ), a traditional Chinese herbal formulation, have been employed as a hospital preparation at Beijing Hospital of Traditional Chinese Medicine for over three decades, primarily for the management of glucose metabolism disorders, with an annual treatment cohort exceeding 1,000 patients. Although preliminary clinical observations suggest potential benefits of YQSJ in patients with hypertension complicated by diabetes, robust evidence from standardized clinical trials is lacking. Therefore, a well-controlled clinical study is warranted to systematically evaluate the efficacy and safety of YQSJ in this specific population. Methods/design: This will be a randomized, double-blind, placebo-controlled study. After being screened and providing signed informed consent, participants will be evenly assigned to experimental or control groups in a 1:1 ratio. The experimental group will receive YQSJ 3 g twice daily and losartan 50 mg once daily, whereas the control group will receive YQSJ placebo 3 g twice daily and losartan 50 mg once daily. The treatment period will last for a total of 8 weeks (56 days), with follow-up visits scheduled every 2 weeks. The primary endpoint will be the difference in drug efficiency between the two groups. The secondary endpoints include 24 h blood pressure indicators, glucose metabolism indicators, lipid metabolism indicators, vascular damage indicators, insulin resistance indicators, oxidative stress indicators, and major adverse cardiovascular events (MACE). Safety and efficacy outcomes will be assessed both before and after the 8-week medication period. Discussion: This study aims to provide clinical evidence on the efficacy and safety of YQSJ in the treatment of hypertension in patients with abnormal glucose metabolism. Furthermore, we will explore the potential mechanism through which YQSJ might exert hypotensive effects and adjust glucose metabolism by examining pertinent indicators of vascular and oxidative stress, as well as its influence on clinical symptoms, risk factors associated with hypertension, and the target organs affected by this condition. Clinical Trial Registration: identifier ChiCTR2200062453.
- 11 May 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1793094
Open AccessEffect and safety of Yiqi-Shengjin granules in hypertension management among patients with abnormal glucose metabolism: a study protocol for a randomized, double-blind, placebo-controlled clinical trial
Background: The co-occurrence of hypertension and abnormal glucose metabolism—a spectrum encompassing prediabetes and diabetes—substantially elevates the risk of cardiovascular disease (CVD). Effective management of this high-risk clinical overlap remains a therapeutic challenge. Yiqi-Shengjin granules (YQSJ), a traditional Chinese herbal formulation, have been employed as a hospital preparation at Beijing Hospital of Traditional Chinese Medicine for over three decades, primarily for the management of glucose metabolism disorders, with an annual treatment cohort exceeding 1,000 patients. Although preliminary clinical observations suggest potential benefits of YQSJ in patients with hypertension complicated by diabetes, robust evidence from standardized clinical trials is lacking. Therefore, a well-controlled clinical study is warranted to systematically evaluate the efficacy and safety of YQSJ in this specific population. Methods/design: This will be a randomized, double-blind, placebo-controlled study. After being screened and providing signed informed consent, participants will be evenly assigned to experimental or control groups in a 1:1 ratio. The experimental group will receive YQSJ 3 g twice daily and losartan 50 mg once daily, whereas the control group will receive YQSJ placebo 3 g twice daily and losartan 50 mg once daily. The treatment period will last for a total of 8 weeks (56 days), with follow-up visits scheduled every 2 weeks. The primary endpoint will be the difference in drug efficiency between the two groups. The secondary endpoints include 24 h blood pressure indicators, glucose metabolism indicators, lipid metabolism indicators, vascular damage indicators, insulin resistance indicators, oxidative stress indicators, and major adverse cardiovascular events (MACE). Safety and efficacy outcomes will be assessed both before and after the 8-week medication period. Discussion: This study aims to provide clinical evidence on the efficacy and safety of YQSJ in the treatment of hypertension in patients with abnormal glucose metabolism. Furthermore, we will explore the potential mechanism through which YQSJ might exert hypotensive effects and adjust glucose metabolism by examining pertinent indicators of vascular and oxidative stress, as well as its influence on clinical symptoms, risk factors associated with hypertension, and the target organs affected by this condition. Clinical Trial Registration: identifier ChiCTR2200062453.
- Open Access
- 28 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 42770
Astragalus membranaceus injection activates mitophagy and protects mitochondrial function in chronic heart failure via inhibiting AKT/mTOR pathway
To investigate the effects and mechanisms of Astragalus Membranaceus Injection (AMI) on mitophagy and mitochondrial function in chronic heart failure (CHF) based on phosphoproteomic and network pharmacology analysis. Primary neonatal mouse cardiomyocytes were isolated and hypertrophy cardiomyocyte model was induced by phenylephrine (PE) stimulation. AMI’s effects on cell size, apoptosis, mitophagy, and mitochondrial function in hypertrophic cardiomyocytes were assessed. A pressure-overload CHF model was established via transverse aortic constriction (TAC) surgery in C57BL/6N mice. Echocardiography and histopathology were employed to evaluate AMI’s effects on cardiac function and structural remodeling. Transmission electron microscope (TEM) and immunofluorescence were used to detect the distribution of autophagosomes and mitochondria. Phosphorylation-antibody microarray and network pharmacology were employed to explore AMI’s cardioprotective mechanisms. The AKT/mTOR pathway’s involvement was verified through Western blotting of AKTSer473 and mTORSer2481 phosphorylation and pharmacological validation using SC79 (AKT/mTOR activator) and GSK-690693 (AKT/mTOR inhibitor) in gain/loss-of-function experiments. In vitro, AMI dose-dependently suppressed pathological hypertrophy, attenuated apoptosis, restored mitochondrial function, and enhanced mitophagic flux. In vivo, AMI treatment significantly improved left ventricular ejection fraction while attenuated cardiac hypertrophy and interstitial fibrosis in TAC-induced CHF mice. Besides, AMI treatment increased the number of mitochondria and elevated autophagy in TAC mice. Phosphoproteomic screening and network pharmacology analysis identified the PI3K/AKT/mTOR axis as the primary regulatory pathway mediating AMI’s cardioprotection. Pharmacological activation of AKT/mTOR signaling using SC79 significantly suppressed mitophagic flux, whereas AMI treatment mirrored the effects of the AKT/mTOR inhibitor GSK-690693, effectively restoring mitophagy and mitochondrial homeostasis. AMI exerts its cardioprotective effects through inhibition of the AKT/mTOR pathway, thereby ameliorating maladaptive remodeling and mitochondrial dysfunction in CHF.
- 28 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 42770
Open AccessAstragalus membranaceus injection activates mitophagy and protects mitochondrial function in chronic heart failure via inhibiting AKT/mTOR pathway
To investigate the effects and mechanisms of Astragalus Membranaceus Injection (AMI) on mitophagy and mitochondrial function in chronic heart failure (CHF) based on phosphoproteomic and network pharmacology analysis. Primary neonatal mouse cardiomyocytes were isolated and hypertrophy cardiomyocyte model was induced by phenylephrine (PE) stimulation. AMI’s effects on cell size, apoptosis, mitophagy, and mitochondrial function in hypertrophic cardiomyocytes were assessed. A pressure-overload CHF model was established via transverse aortic constriction (TAC) surgery in C57BL/6N mice. Echocardiography and histopathology were employed to evaluate AMI’s effects on cardiac function and structural remodeling. Transmission electron microscope (TEM) and immunofluorescence were used to detect the distribution of autophagosomes and mitochondria. Phosphorylation-antibody microarray and network pharmacology were employed to explore AMI’s cardioprotective mechanisms. The AKT/mTOR pathway’s involvement was verified through Western blotting of AKTSer473 and mTORSer2481 phosphorylation and pharmacological validation using SC79 (AKT/mTOR activator) and GSK-690693 (AKT/mTOR inhibitor) in gain/loss-of-function experiments. In vitro, AMI dose-dependently suppressed pathological hypertrophy, attenuated apoptosis, restored mitochondrial function, and enhanced mitophagic flux. In vivo, AMI treatment significantly improved left ventricular ejection fraction while attenuated cardiac hypertrophy and interstitial fibrosis in TAC-induced CHF mice. Besides, AMI treatment increased the number of mitochondria and elevated autophagy in TAC mice. Phosphoproteomic screening and network pharmacology analysis identified the PI3K/AKT/mTOR axis as the primary regulatory pathway mediating AMI’s cardioprotection. Pharmacological activation of AKT/mTOR signaling using SC79 significantly suppressed mitophagic flux, whereas AMI treatment mirrored the effects of the AKT/mTOR inhibitor GSK-690693, effectively restoring mitophagy and mitochondrial homeostasis. AMI exerts its cardioprotective effects through inhibition of the AKT/mTOR pathway, thereby ameliorating maladaptive remodeling and mitochondrial dysfunction in CHF.
- Open Access
- 10 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (41) , e44990
Multiple anthropometric characteristics and Brugada syndrome: A Mendelian randomization study
Brugada syndrome (BrS) has been associated with lower obesity rates and reduced body mass index (BMI) in observational studies. This Mendelian randomization (MR) study investigates causal effects of anthropometric traits on the risk of BrS. Two-sample MR analyses were conducted using publicly available genome-wide association study summary statistics, and both discovery and replication datasets were incorporated. The inverse-variance weighted method was the primary analytical approach, supported by MR-Egger and weighted median methods. Sensitivity analyses (including Cochran Q test, MR-Egger intercept test, MR-PRESSO global test, and leave-one-out analysis) were performed to assess the robustness of the results. Genetically predicted comparative body size at age 10 showed significant inverse associations with BrS risk (discovery: odds ratio [OR] = 0.40, 95% confidence interval [CI]: 0.26–0.61, P = 2.07 × 10 −5 ; replication: OR = 0.47, 95% CI: 0.31–0.71, P = 3.68 × 10 −4 ). Similarly, adult obesity was inversely associated with BrS in the discovery set (OR = 0.78, 95% CI: 0.69–0.89, P = 1.42 × 10 −4 ). Genetically predicted childhood obesity, whole-body fat-free mass, BMI, waist-to-hip ratio, and basal metabolic rate also demonstrated potential protective effects (discovery: all P < .05). Reverse MR analysis revealed positive associations between genetically predicted BrS and both waist and hip circumference ( P < .005). This study suggests that genetically higher childhood/adult obesity and increased fat-free mass may reduce the risk of BrS. Maintaining a BMI in the upper-normal range and enhancing fat-free mass through resistance training may represent a viable strategy to mitigate BrS risk.
- 10 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (41) , e44990
Open AccessMultiple anthropometric characteristics and Brugada syndrome: A Mendelian randomization study
Brugada syndrome (BrS) has been associated with lower obesity rates and reduced body mass index (BMI) in observational studies. This Mendelian randomization (MR) study investigates causal effects of anthropometric traits on the risk of BrS. Two-sample MR analyses were conducted using publicly available genome-wide association study summary statistics, and both discovery and replication datasets were incorporated. The inverse-variance weighted method was the primary analytical approach, supported by MR-Egger and weighted median methods. Sensitivity analyses (including Cochran Q test, MR-Egger intercept test, MR-PRESSO global test, and leave-one-out analysis) were performed to assess the robustness of the results. Genetically predicted comparative body size at age 10 showed significant inverse associations with BrS risk (discovery: odds ratio [OR] = 0.40, 95% confidence interval [CI]: 0.26–0.61, P = 2.07 × 10 −5 ; replication: OR = 0.47, 95% CI: 0.31–0.71, P = 3.68 × 10 −4 ). Similarly, adult obesity was inversely associated with BrS in the discovery set (OR = 0.78, 95% CI: 0.69–0.89, P = 1.42 × 10 −4 ). Genetically predicted childhood obesity, whole-body fat-free mass, BMI, waist-to-hip ratio, and basal metabolic rate also demonstrated potential protective effects (discovery: all P < .05). Reverse MR analysis revealed positive associations between genetically predicted BrS and both waist and hip circumference ( P < .005). This study suggests that genetically higher childhood/adult obesity and increased fat-free mass may reduce the risk of BrS. Maintaining a BMI in the upper-normal range and enhancing fat-free mass through resistance training may represent a viable strategy to mitigate BrS risk.
- Open Access
- 24 September 2025
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 61, 102024
Comparative efficacy and safety of Chinese patent medicines as adjunctive therapies for glycolipid regulation in metabolic syndrome: A network meta-analysis
- 24 September 2025
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 61, 102024
Open AccessComparative efficacy and safety of Chinese patent medicines as adjunctive therapies for glycolipid regulation in metabolic syndrome: A network meta-analysis
- Open Access
- 31 July 2025
- Published by AccScience Publishing in Advanced Neurology
- Vol. 5 (1) , 30
Facilitating recovery from post-stroke depression with acupuncture: A comprehensive analysis of systematic reviews
Post-stroke depression (PSD) is the most common psychological complication among stroke survivors and is strongly associated with poor outcomes and increased mortality. Acupuncture has been proposed as a potential treatment for PSD. In this overview, 13 meta-analyses (MAs) of randomized controlled trials published up to August 2023 that evaluated acupuncture for PSD were identified. Across these MAs, acupuncture generally demonstrated greater efficacy than control interventions in alleviating depressive symptoms. However, methodological assessment using the A MeaSurement Tool to Assess Systematic Reviews 2 (AMSTAR-2) rated all included studies as having critically low quality, indicating pervasive design and reporting weaknesses. Reporting quality, as evaluated by the Preferred Reporting Items for Systematic Reviews and MAs guidelines, was relatively high, with over 90% of checklist items being rated “yes” or “partially yes.” When the quality of evidence was appraised through the grading of recommendations assessment, development, and evaluation system, only nine of 61 outcomes were classified as moderate quality, 29 as low quality, and the remainder as very low quality. Although acupuncture appears to be a safe and potentially beneficial option for managing PSD, the overall strength of evidence remains limited. Thus, these findings should be interpreted with caution. Future research should prioritize rigorous trial design, standardized intervention protocols, and comprehensive meta-analytic methods to enhance the reliability and clinical applicability of evidence on acupuncture for PSD.
- 31 July 2025
- Published by AccScience Publishing in Advanced Neurology
- Vol. 5 (1) , 30
Open AccessFacilitating recovery from post-stroke depression with acupuncture: A comprehensive analysis of systematic reviews
Post-stroke depression (PSD) is the most common psychological complication among stroke survivors and is strongly associated with poor outcomes and increased mortality. Acupuncture has been proposed as a potential treatment for PSD. In this overview, 13 meta-analyses (MAs) of randomized controlled trials published up to August 2023 that evaluated acupuncture for PSD were identified. Across these MAs, acupuncture generally demonstrated greater efficacy than control interventions in alleviating depressive symptoms. However, methodological assessment using the A MeaSurement Tool to Assess Systematic Reviews 2 (AMSTAR-2) rated all included studies as having critically low quality, indicating pervasive design and reporting weaknesses. Reporting quality, as evaluated by the Preferred Reporting Items for Systematic Reviews and MAs guidelines, was relatively high, with over 90% of checklist items being rated “yes” or “partially yes.” When the quality of evidence was appraised through the grading of recommendations assessment, development, and evaluation system, only nine of 61 outcomes were classified as moderate quality, 29 as low quality, and the remainder as very low quality. Although acupuncture appears to be a safe and potentially beneficial option for managing PSD, the overall strength of evidence remains limited. Thus, these findings should be interpreted with caution. Future research should prioritize rigorous trial design, standardized intervention protocols, and comprehensive meta-analytic methods to enhance the reliability and clinical applicability of evidence on acupuncture for PSD.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 18, 3357-3372
Global Research Trends in Oxidative Stress and Myocardial Fibrosis: A Dual-Software Bibliometric Study
Objective: To conduct a visualization analysis of the literature on the role of oxidative stress in myocardial fibrosis (MF), explore the research progress, frontier hotspots, and development trends in this field, with the aim of providing a reference for the research on the prevention and treatment of MF related to oxidative stress. Methods: Web of Science was selected as the data source, and the relevant English literature on the role of oxidative stress in MF from the database establishment to December 31, 2024 was collected. Bibliometric methods were used for statistical analysis of the literature that met the research standards, and CiteSpace 6.3.R2 and VOSviewer 1.6.20 software were used for visualization of information such as publishing countries, institutions, authors, and keywords. Results: A total of 1831 SCI articles were included. The global publication volume showed an upward trend year by year, Publications increased by 16% annually after 2014, with China and the United States leading in publication volume. Keyword and cited literature analysis showed that the research hotspots and frontiers in this field mainly include the phenomenon of extracellular matrix (ECM) cell migration, the activation of the renin-angiotensin-aldosterone system, the regulatory mechanisms of oxidative stress in MF of different etiologies, and the mechanisms of action of oxidative stress in MF. Conclusion: The field of research into the role of oxidative stress in myocardial fibrosis is currently experiencing a period of rapid expansion. By leveraging the complementary strengths of CiteSpace for analyzing temporal and geographic trends, and VOSviewer for mapping collaboration networks, researchers have gained multidimensional insights into this area. The identification of the NLRP3 inflammasome as the fastest-growing research frontier, highlights its potential as a novel therapeutic target for clinical investigation. The mechanism by which oxidative stress activates the NLRP3 inflammasome signaling pathway to promote myocardial fibrosis is likely to emerge as a significant future research trend and warrants further in-depth exploration and study.
- 1 June 2025
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 18, 3357-3372
Open AccessGlobal Research Trends in Oxidative Stress and Myocardial Fibrosis: A Dual-Software Bibliometric Study
Objective: To conduct a visualization analysis of the literature on the role of oxidative stress in myocardial fibrosis (MF), explore the research progress, frontier hotspots, and development trends in this field, with the aim of providing a reference for the research on the prevention and treatment of MF related to oxidative stress. Methods: Web of Science was selected as the data source, and the relevant English literature on the role of oxidative stress in MF from the database establishment to December 31, 2024 was collected. Bibliometric methods were used for statistical analysis of the literature that met the research standards, and CiteSpace 6.3.R2 and VOSviewer 1.6.20 software were used for visualization of information such as publishing countries, institutions, authors, and keywords. Results: A total of 1831 SCI articles were included. The global publication volume showed an upward trend year by year, Publications increased by 16% annually after 2014, with China and the United States leading in publication volume. Keyword and cited literature analysis showed that the research hotspots and frontiers in this field mainly include the phenomenon of extracellular matrix (ECM) cell migration, the activation of the renin-angiotensin-aldosterone system, the regulatory mechanisms of oxidative stress in MF of different etiologies, and the mechanisms of action of oxidative stress in MF. Conclusion: The field of research into the role of oxidative stress in myocardial fibrosis is currently experiencing a period of rapid expansion. By leveraging the complementary strengths of CiteSpace for analyzing temporal and geographic trends, and VOSviewer for mapping collaboration networks, researchers have gained multidimensional insights into this area. The identification of the NLRP3 inflammasome as the fastest-growing research frontier, highlights its potential as a novel therapeutic target for clinical investigation. The mechanism by which oxidative stress activates the NLRP3 inflammasome signaling pathway to promote myocardial fibrosis is likely to emerge as a significant future research trend and warrants further in-depth exploration and study.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 18, 697-710
Global Research Trends and Focus on the Link Between Heart Failure and NLRP3 Inflammasome: A Bibliometric Analysis From 2010 to 2024
Background: Heart failure (HF) is characterized by elevated morbidity, mortality, and rehospitalization frequencies. This condition imposes a considerable medical burden and fiscal strain on society. Inflammation plays a crucial role in the inception, advancement, and outcome of HF. Despite mounting evidence demonstrating the pivotal function of the NLRP3 inflammasome in HF, a thorough bibliometric examination of research focal points and trajectories in this domain has yet to be undertaken. Methods: Publications related to the NLRP3 inflammasome in HF were retrieved from the Web of Science database spanning 2010– 2024. The acquired data were subsequently analyzed utilizing various visualization instruments, including Citespace, VOSviewer, Scimago Graphica, and Microsoft Office Excel 2021. Results: A total of 282 papers were included in the analysis, authored by 2,130 researchers from 500 institutions across 34 nations/regions. China emerged as a significant contributor to this field, producing the highest number of outputs. Antonio Abbate was identified as the most prolific author. Virginia Commonwealth University and Wuhan University were the institutions with the highest publication output. INTERNATIONAL IMMUNOPHARMACOLOGY was the periodical with the most numerous publications in this sphere. CIRCULATION, however, received the highest number of citations, indicating its substantial influence on investigations in this field. Contemporary research focal points primarily concentrate on the activation and inhibition pathways of the NLRP3 inflammasome, the exploration of novel HF targets, and the association between HF and mitochondrial function. Future research trajectories are likely to encompass investigations into the relationship between HF and pyroptosis, as well as clinical studies on pharmaceuticals targeting the NLRP3 inflammasome as a therapeutic approach for HF. Conclusion: This investigation provides a comprehensive bibliometric analysis and synopsis of NLRP3 inflammable-related studies in HF. The findings offer a conceptual foundation for further research on the NLRP3 inflammasome in HF and provide valuable guidance for future research directions in this domain.
- 1 February 2025
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 18, 697-710
Open AccessGlobal Research Trends and Focus on the Link Between Heart Failure and NLRP3 Inflammasome: A Bibliometric Analysis From 2010 to 2024
Background: Heart failure (HF) is characterized by elevated morbidity, mortality, and rehospitalization frequencies. This condition imposes a considerable medical burden and fiscal strain on society. Inflammation plays a crucial role in the inception, advancement, and outcome of HF. Despite mounting evidence demonstrating the pivotal function of the NLRP3 inflammasome in HF, a thorough bibliometric examination of research focal points and trajectories in this domain has yet to be undertaken. Methods: Publications related to the NLRP3 inflammasome in HF were retrieved from the Web of Science database spanning 2010– 2024. The acquired data were subsequently analyzed utilizing various visualization instruments, including Citespace, VOSviewer, Scimago Graphica, and Microsoft Office Excel 2021. Results: A total of 282 papers were included in the analysis, authored by 2,130 researchers from 500 institutions across 34 nations/regions. China emerged as a significant contributor to this field, producing the highest number of outputs. Antonio Abbate was identified as the most prolific author. Virginia Commonwealth University and Wuhan University were the institutions with the highest publication output. INTERNATIONAL IMMUNOPHARMACOLOGY was the periodical with the most numerous publications in this sphere. CIRCULATION, however, received the highest number of citations, indicating its substantial influence on investigations in this field. Contemporary research focal points primarily concentrate on the activation and inhibition pathways of the NLRP3 inflammasome, the exploration of novel HF targets, and the association between HF and mitochondrial function. Future research trajectories are likely to encompass investigations into the relationship between HF and pyroptosis, as well as clinical studies on pharmaceuticals targeting the NLRP3 inflammasome as a therapeutic approach for HF. Conclusion: This investigation provides a comprehensive bibliometric analysis and synopsis of NLRP3 inflammable-related studies in HF. The findings offer a conceptual foundation for further research on the NLRP3 inflammasome in HF and provide valuable guidance for future research directions in this domain.
- Open Access
Mechanisms of traditional Chinese medicine in modulating cardiac microvascular endothelial cells in various injury models: A comprehensive systematic review
Background The structural and functional failure of cardiac microvascular endothelial cells (CMECs) is a primary contributor to coronary microvascular dysfunction (CMD). Traditional Chinese medicine (TCM) has been identified as a potential therapeutic approach for preserving CMECs and mitigating CMD. Objective This systematic review aims to present the latest evidence on TCM intervention mechanisms in CMECs under diverse injury models. Methods This systematic review was performed following the parameters of the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-Analysis). A comprehensive literature search was conducted using PubMed, Embase, Web of Science, Scopus, China National Knowledge Infrastructure and China Biology Medicine disc. Reference lists of selected articles were reviewed to identify relevant studies. The search was not limited by year and was conducted solely in English. Eligible studies comprised publications describing in vitro studies that presented the latest evidence on TCM intervention mechanisms in CMECs under diverse injury models. Results A total of 63 papers were included in this study. According to the cell processing approach, 19 studies on ischemia or hypoxic injury models, 16 studies on Ischemia/reperfusion (I/R) or hypoxia/reoxygenation (H/R) injury models, 10 studies on inflammatory injury models, 5 studies on metabolic injury models, 3 studies on angiotensin II injury models, and 10 studies on other models. TCM exhibits structural and functional intervention capabilities in diverse damage conditions of CMECs. Its mechanism of action involves antioxidant, anti-apoptotic, anti-inflammatory effects, as well as regulation of energy metabolism through signaling pathways such as HIF-1α/VEGF, PI3K/AKT, MAPK, and NF-κB. Conclusions The CCM and its constituents modulate CMECs through multiple signaling pathways in response to various injury models, thereby conferring protection on the coronary microcirculation.
Open AccessMechanisms of traditional Chinese medicine in modulating cardiac microvascular endothelial cells in various injury models: A comprehensive systematic review
Background The structural and functional failure of cardiac microvascular endothelial cells (CMECs) is a primary contributor to coronary microvascular dysfunction (CMD). Traditional Chinese medicine (TCM) has been identified as a potential therapeutic approach for preserving CMECs and mitigating CMD. Objective This systematic review aims to present the latest evidence on TCM intervention mechanisms in CMECs under diverse injury models. Methods This systematic review was performed following the parameters of the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-Analysis). A comprehensive literature search was conducted using PubMed, Embase, Web of Science, Scopus, China National Knowledge Infrastructure and China Biology Medicine disc. Reference lists of selected articles were reviewed to identify relevant studies. The search was not limited by year and was conducted solely in English. Eligible studies comprised publications describing in vitro studies that presented the latest evidence on TCM intervention mechanisms in CMECs under diverse injury models. Results A total of 63 papers were included in this study. According to the cell processing approach, 19 studies on ischemia or hypoxic injury models, 16 studies on Ischemia/reperfusion (I/R) or hypoxia/reoxygenation (H/R) injury models, 10 studies on inflammatory injury models, 5 studies on metabolic injury models, 3 studies on angiotensin II injury models, and 10 studies on other models. TCM exhibits structural and functional intervention capabilities in diverse damage conditions of CMECs. Its mechanism of action involves antioxidant, anti-apoptotic, anti-inflammatory effects, as well as regulation of energy metabolism through signaling pathways such as HIF-1α/VEGF, PI3K/AKT, MAPK, and NF-κB. Conclusions The CCM and its constituents modulate CMECs through multiple signaling pathways in response to various injury models, thereby conferring protection on the coronary microcirculation.